These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 26271358)

  • 21. Short-term outcomes of laparoscopic surgery for Crohn's disease patients treated with anti-tumor necrosis factor alpha agents.
    Hata T; Mizushima T; Osawa H; Takahashi H; Haraguchi N; Nishimura J; Hata T; Takemasa I; Ikenaga M; Nakajima K; Yamamoto H; Murata K; Doki Y; Mori M
    Surg Today; 2017 Mar; 47(3):320-327. PubMed ID: 27372080
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The appropriateness of concomitant immunomodulators with anti-tumor necrosis factor agents for Crohn's disease: one size does not fit all.
    Melmed GY; Spiegel BM; Bressler B; Cheifetz AS; Devlin SM; Harrell LE; Irving PM; Jones J; Kaplan GG; Kozuch PL; Velayos FS; Baidoo L; Sparrow MP; Siegel CA
    Clin Gastroenterol Hepatol; 2010 Aug; 8(8):655-9. PubMed ID: 20451665
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of infliximab with adalimumab in 827 biologic-naïve patients with Crohn's disease: a population-based Danish cohort study.
    Singh S; Andersen NN; Andersson M; Loftus EV; Jess T
    Aliment Pharmacol Ther; 2018 Mar; 47(5):596-604. PubMed ID: 29239001
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term MRI-guided combined anti-TNF-α and thiopurine therapy for Crohn's perianal fistulas.
    Tozer P; Ng SC; Siddiqui MR; Plamondon S; Burling D; Gupta A; Swatton A; Tripoli S; Vaizey CJ; Kamm MA; Phillips R; Hart A
    Inflamm Bowel Dis; 2012 Oct; 18(10):1825-34. PubMed ID: 22223472
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment Persistence for Infliximab Versus Adalimumab in Crohn's Disease: A 14-Year Single-Center Experience.
    Olivera P; Thiriet L; Luc A; Baumann C; Danese S; Peyrin-Biroulet L
    Inflamm Bowel Dis; 2017 Jun; 23(6):976-985. PubMed ID: 28333755
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Experience With Anti-TNF-α Biologic Agents in Succession in Patients With Crohn's Disease: A Retrospective Analysis of a Single Center.
    Ferges W; Rampertab SD; Shafqet M; Salimi Q; You G; Yousefzadeh E; Cheng JQ; Das KM
    J Clin Gastroenterol; 2016 Apr; 50(4):326-30. PubMed ID: 25984976
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A validated web-based tool to display individualised Crohn's disease predicted outcomes based on clinical, serologic and genetic variables.
    Siegel CA; Horton H; Siegel LS; Thompson KD; Mackenzie T; Stewart SK; Rice PW; Stempak JM; Dezfoli S; Haritunians T; Levy A; Baek M; Milgrom R; Dulai PS; Targan SR; Silverberg MS; Dubinsky MC; McGovern DP
    Aliment Pharmacol Ther; 2016 Jan; 43(2):262-71. PubMed ID: 26567467
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Certolizumab pegol: new drug. As a last resort in Crohn's disease: continue to use other TNF alpha inhibitors.
    Prescrire Int; 2009 Jun; 18(101):108-10. PubMed ID: 19637418
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Analysis of TNF-antagonist switch over time and associated risk factors in the Swiss Inflammatory Bowel Disease Cohort.
    Hiroz P; Vavricka SR; Fournier N; Safroneeva E; Pittet V; Rogler G; Schoepfer AM;
    Scand J Gastroenterol; 2014 Oct; 49(10):1207-18. PubMed ID: 25120029
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Early treatment with anti-tumor necrosis factor agents improves long-term effectiveness in symptomatic stricturing Crohn's disease.
    Rodríguez-Lago I; Hoyo JD; Pérez-Girbés A; Garrido-Marín A; Casanova MJ; Chaparro M; Fernández-Clotet A; Castro-Poceiro J; García MJ; Sánchez S; Ferreiro-Iglesias R; Bastón I; Piqueras M; Careda LEIB; Mena R; Suárez C; Cordón JP; López-García A; Márquez L; Arroyo M; Alfambra E; Sierra M; Cano N; Delgado-Guillena P; Morales-Alvarado V; Aparicio JC; Guerra I; Aulló C; Merino O; Arranz L; Hidalgo MA; Llaó J; Plaza R; Molina G; Torres P; Pérez-Galindo P; Romero MG; Herrera-deGuise C; Armesto E; Mesonero F; Frago-Larramona S; Benítez JM; Calvo M; Martín MDCL; Elorza A; Larena A; Peña E; Rodríguez-Grau MDC; Miguel-Criado J; Botella B; Olmos JA; López L; Aguirre U; Gisbert JP;
    United European Gastroenterol J; 2020 Nov; 8(9):1056-1066. PubMed ID: 32723069
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Influence of age at diagnosis on the clinical characteristics of Crohn's disease in Korea: Results from the CONNECT study.
    Hwang SW; Kim JH; Im JP; Ye BD; Koo HS; Huh KC; Cheon JH; Kim YS; Kim YH; Han DS; Kim WH; Kim JS;
    J Gastroenterol Hepatol; 2017 Oct; 32(10):1716-1722. PubMed ID: 28251684
    [TBL] [Abstract][Full Text] [Related]  

  • 32. TNF-alpha antagonist induced lupus on three different agents.
    Mudduluru BM; Shah S; Shamah S; Swaminath A
    Postgrad Med; 2017 Mar; 129(2):304-306. PubMed ID: 27748629
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunomodulators are associated with a lower risk of first surgery among patients with non-penetrating non-stricturing Crohn's disease.
    Picco MF; Zubiaurre I; Adluni M; Cangemi JR; Shelton D
    Am J Gastroenterol; 2009 Nov; 104(11):2754-9. PubMed ID: 19584832
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Relapse after withdrawal from anti-TNF therapy for inflammatory bowel disease: an observational study, plus systematic review and meta-analysis.
    Kennedy NA; Warner B; Johnston EL; Flanders L; Hendy P; Ding NS; Harris R; Fadra AS; Basquill C; Lamb CA; Cameron FL; Murray CD; Parkes M; Gooding I; Ahmad T; Gaya DR; Mann S; Lindsay JO; Gordon J; Satsangi J; Hart A; McCartney S; Irving P; ; Lees CW
    Aliment Pharmacol Ther; 2016 Apr; 43(8):910-923. PubMed ID: 26892328
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tumor Necrosis Factor Alpha Inhibitors Did Not Influence Postoperative Morbidity After Elective Surgical Resections in Crohn's Disease.
    Kotze PG; Saab MP; Saab B; da Silva Kotze LM; Olandoski M; Pinheiro LV; Martinez CA; Ayrizono ML; Magro DO; Coy CS
    Dig Dis Sci; 2017 Feb; 62(2):456-464. PubMed ID: 27933472
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Early use of thiopurines or methotrexate reduces major abdominal and perianal surgery in Crohn's disease.
    Kariyawasam VC; Selinger CP; Katelaris PH; Jones DB; McDonald C; Barr G; Chapman G; Colliwshaw J; Lunney PC; Middleton K; Wang RR; Huang T; Andrews J; Leong RW
    Inflamm Bowel Dis; 2014 Aug; 20(8):1382-90. PubMed ID: 24991785
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term outcome of perianal fistulizing Crohn's disease treated with infliximab.
    Bouguen G; Siproudhis L; Gizard E; Wallenhorst T; Billioud V; Bretagne JF; Bigard MA; Peyrin-Biroulet L
    Clin Gastroenterol Hepatol; 2013 Aug; 11(8):975-81.e1-4. PubMed ID: 23376316
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Indicators of suboptimal tumor necrosis factor antagonist therapy in inflammatory bowel disease.
    Lindsay JO; Armuzzi A; Gisbert JP; Bokemeyer B; Peyrin-Biroulet L; Nguyen GC; Smyth M; Patel H
    Dig Liver Dis; 2017 Oct; 49(10):1086-1091. PubMed ID: 28826571
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A comprehensive review and update on Crohn's disease.
    Gajendran M; Loganathan P; Catinella AP; Hashash JG
    Dis Mon; 2018 Feb; 64(2):20-57. PubMed ID: 28826742
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of tumour necrosis factor antagonists in stricturing Crohn's disease: A tertiary center real-life experience.
    Allocca M; Bonifacio C; Fiorino G; Spinelli A; Furfaro F; Balzarini L; Bonovas S; Danese S
    Dig Liver Dis; 2017 Aug; 49(8):872-877. PubMed ID: 28416240
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.